CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a patient's own immune T cells and engineering them to recognize specific targets ...

Read about exa-cel being rolled out on the NHS, providing a 'functional cure' for some patients with severe sickle cell ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

President Trump signed an executive order on the day of his inauguration that created doubts about the future of a program to ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the ...

NHS officials estimate around 50 people a year will receive treatment now it has been approved for use for certain patients with severe sickle cell disease. | ITV National News ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.

The National Institute for Health and Care Excellence (NICE) has approved Vertex Pharmaceuticals’ Casgevy (exagamglogene ...

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...